Investor group forms Accentia

A group of investors led by Hopkins Capital Group formed Accentia (Morrisville, N.C.), which will develop therapeutics for respiratory and critical care oncology indications. Accentia combines Hopkins acquisitions Analytica and TEAMM, plus a majority interest in BioVest International. The new company markets Respi-TANN carbetapentane/pseudoephedrine and the Histex line of products to treat cough, cold and allergy. Accentia also will market recently approved pain drug Xodol hydrocodone/acetaminophen combination and co-promote dermatology products Alcortin and Novacort with Primus (Scottsdale, Ariz.). ...